Concepedia

Matthew R. Janes

MR

Statistics

Publications

20

Citations

5.1K

H-Index

18

Active since

2008

Affiliations

University of California, Irvine(Current)

Wellspring Biosciences (United States)

Intel (United States)

Kura Oncology (United States)

National University of Singapore

Matthew R. Janes is an author at University of California, Irvine specializing in oncology, molecular oncology, and medicine.

Publications per year

2008–2020

20

Publications

20

The translational landscape of mTOR signalling steers cancer initiation and metastasis

Andrew C. Hsieh, Yi Liu, Merritt P. Edlind et al. · Nature · 2012 · 1.4K citations

Medicine, Cancer Biology, Oncology +14

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Matthew R. Janes, Jingchuan Zhang, Lian‐Sheng Li et al. · Cell · 2018 · 1.2K citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +12

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

Matthew P. Patricelli, Matthew R. Janes, Lian‐Sheng Li et al. · Cancer Discovery · 2016 · 754 citations · Full text

Medicine, Medicinal Chemistry, Oncology +17

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

Matthew R. Janes, Jose J. Limon, Lomon So et al. · Nature Medicine · 2010 · 338 citations · Full text

Medicine, Oncology, Pharmacology +14

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Sandra Misale, Jackson P. Fatherree, Eliane Cortez et al. · Clinical Cancer Research · 2018 · 267 citations

Medicine, Oncology, Pharmacology +14

1–5 of 20